Bicycle Therapeutics (BCYC) Accounts Payables (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Accounts Payables came in at $5.7 million in Q2 2026, down 69.0% YoY from $18.3 million in Q2 2025, and down 5.16% on a QoQ basis from $6.0 million in Q1 2026.
Bicycle Therapeutics (BCYC) Accounts Payables (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Accounts Payables data on file, last reported at $5.7 million in Q2 2026.
- Quarterly Accounts Payables fell 69.0% year-over-year to $5.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.7 million (down 69.0% YoY) and the FY2025 annual result came in at $9.7 million, down 38.78% from the prior year.
- Accounts Payables eased to $5.7 million in Q2 2026, from $6.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $18.3 million in Q2 2025 to a low of $2.8 million in Q1 2023.
- A 5-year average of $8.4 million and a median of $7.1 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables soared 301.51% — and 2026, when it sank 69.0%.
- Tracing BCYC's Accounts Payables over 5 years: stood at $6.5 million in 2022, then surged by 101.64% to $13.0 million in 2023, then climbed by 21.02% to $15.8 million in 2024, then plunged by 38.78% to $9.7 million in 2025, then slumped by 41.44% to $5.7 million in 2026.
- The last three Accounts Payables figures came in at $5.7 million (Q2 2026), $6.0 million (Q1 2026), and $9.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | 5.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.66 Mn |
| Mar 31, 2026 | 5.97 Mn |
| Dec 31, 2025 | 9.67 Mn |
| Sep 30, 2025 | 12.65 Mn |
| Jun 30, 2025 | 18.26 Mn |
| Mar 31, 2025 | 11.11 Mn |
| Dec 31, 2024 | 15.79 Mn |
| Sep 30, 2024 | 5.71 Mn |
| Jun 30, 2024 | 7.45 Mn |
| Mar 31, 2024 | 7.06 Mn |
| Dec 31, 2023 | 13.05 Mn |
| Sep 30, 2023 | 8.49 Mn |
| Jun 30, 2023 | 5.25 Mn |
| Mar 31, 2023 | 2.81 Mn |
| Dec 31, 2022 | 6.47 Mn |
| Sep 30, 2022 | 7.06 Mn |
| Jun 30, 2022 | 4.86 Mn |
| Mar 31, 2022 | 4.00 Mn |
| Dec 31, 2021 | 2.72 Mn |
| Sep 30, 2021 | 1.76 Mn |